These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38311031)

  • 1. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma.
    Corrigan KL; Xu T; Sasaki Y; Lin R; Chen AB; Welsh JW; Lin SH; Chang JY; Ning MS; Gandhi S; O'Reilly MS; Gay CM; Altan M; Lu C; Cascone T; Koutroumpakis E; Sheshadri A; Zhang X; Liao L; Zhu XR; Heymach JV; Nguyen QN; Liao Z
    Radiother Oncol; 2024 Apr; 193():110121. PubMed ID: 38311031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemoimmunotherapy with surgery versus concurrent chemoradiation followed by immunotherapy for stage III-N2 non-small cell lung cancer.
    Kumar A; Srinivasan D; Potter AL; Mathey-Andrews C; Lanuti M; Martin LW; Jeffrey Yang CF
    J Thorac Cardiovasc Surg; 2024 Jun; 167(6):1895-1905.e2. PubMed ID: 37722622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis.
    Chen Y; Luo H; Liu R; Tan M; Wang Q; Wu X; Du T; Liu Z; Sun S; Zhang Q; Wang X
    Radiat Oncol; 2023 May; 18(1):86. PubMed ID: 37217970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton therapy (PT) combined with concurrent chemotherapy for locally advanced non-small cell lung cancer with negative driver genes.
    Jin Y; Shimizu S; Li Y; Yao Y; Liu X; Si H; Sakurai H; Xiao W
    Radiat Oncol; 2023 Nov; 18(1):189. PubMed ID: 37974211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    Ning MS; Tang L; Gomez DR; Xu T; Luo Y; Huo J; Mouhayar E; Liao Z
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):70-79. PubMed ID: 28816165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.
    Yamamoto T; Tsukita Y; Katagiri Y; Matsushita H; Umezawa R; Ishikawa Y; Takahashi N; Suzuki Y; Takeda K; Miyauchi E; Saito R; Katsuta Y; Kadoya N; Jingu K
    BMC Cancer; 2022 Apr; 22(1):364. PubMed ID: 35379201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study.
    Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F
    Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
    Galli G; De Toma A; Pagani F; Randon G; Trevisan B; Prelaj A; Ferrara R; Proto C; Signorelli D; Ganzinelli M; Zilembo N; de Braud F; Garassino MC; Lo Russo G
    Lung Cancer; 2019 Nov; 137():38-42. PubMed ID: 31526910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
    Pons-Tostivint E; Hulo P; Guardiolle V; Bodot L; Rabeau A; Porte M; Hiret S; Demontrond P; Curcio H; Boudoussier A; Veillon R; Mayenga M; Dumenil C; Chatellier T; Gourraud PA; Mazieres J; Bennouna J
    Cancer Immunol Immunother; 2023 Jun; 72(6):1881-1890. PubMed ID: 36690799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes.
    McAvoy S; Ciura K; Wei C; Rineer J; Liao Z; Chang JY; Palmer MB; Cox JD; Komaki R; Gomez DR
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):819-27. PubMed ID: 25220718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib.
    Long Y; Xiong Q; Song Q; Li Y; Li X; Qin B; Huang Z; Hu Y; Yang B
    Thorac Cancer; 2022 Feb; 13(3):394-403. PubMed ID: 34958168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.
    Wang J; Zhou Z; Liang J; Feng Q; Xiao Z; Hui Z; Wang X; Lv J; Chen D; Zhang H; Ji Z; Cao J; Liu L; Jiang W; Men Y; Xu C; Dai J; Yin W; Wang L
    Oncologist; 2016 Dec; 21(12):1530-1537. PubMed ID: 27628491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
    Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD
    JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer.
    Nguyen QN; Ly NB; Komaki R; Levy LB; Gomez DR; Chang JY; Allen PK; Mehran RJ; Lu C; Gillin M; Liao Z; Cox JD
    Radiother Oncol; 2015 Jun; 115(3):367-72. PubMed ID: 26028228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: a propensity-matched analysis.
    Wang X; Yin C; Su S; Li X; Wang C; Zhang C; Liu M
    BMC Cancer; 2018 Nov; 18(1):1067. PubMed ID: 30400782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
    Singh R; Ansinelli H; Sharma D; Jenkins J; Davis J; Vargo JA; Sharma S
    Am J Clin Oncol; 2019 Jul; 42(7):602-606. PubMed ID: 31232723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of definitive radiotherapy for locally advanced non-small cell lung cancer: A real-world single-center study in the pre-durvalumab era.
    Zhu H; Xu Y; Gao H; Fan X; Fan M; Zhao K; Yang H; Zhu Z; Wu K
    Cancer Med; 2024 Aug; 13(15):e70051. PubMed ID: 39082888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Chemotherapy in Addition to Neoadjuvant Chemotherapy for Locally Advanced Non-small Cell Lung Cancer.
    Miyata R; Aoki M; Morizono S; Umehara T; Harada-Takeda A; Kamimura GO; Nagata T; Ueda K
    In Vivo; 2024; 38(5):2515-2522. PubMed ID: 39187348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy.
    Chaunzwa TL; Qian JM; Li Q; Ricciuti B; Nuernberg L; Johnson JW; Weiss J; Zhang Z; MacKay J; Kagiampakis I; Bikiel D; Di Federico A; Alessi JV; Mak RH; Jacob E; Awad MM; Aerts HJWL
    JAMA Oncol; 2024 Jun; 10(6):773-783. PubMed ID: 38780929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
    Williams CD; Allo MA; Gu L; Vashistha V; Press A; Kelley M
    PLoS One; 2023; 18(2):e0282020. PubMed ID: 36809528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.